BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$85.31 USD
+1.22 (1.45%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $85.31 0.00 (0.00%) 4:48 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 801 - 818 ( 818 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials: Revenues A Bit Light. 2010 Guidance Tightened. We See 2011 As A Potential Inflection With Multiple Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Preview: We See An In-Line Q3 With A Substantial One-Time Tax Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with a Neutral Rating and 12-Month Price Target of $26
Provider: DAWSON JAMES SECURITIES, INC.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company Acquires Early Stage Drug Candidate for Pompe Disease.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials Missed And 2010 Guidance Was Lowered. Pipeline Progress: So Far So Good For PEG-PAL.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Consensus And Comparables: We Believe Q2 Consensus Is Achievable.Is Trading In-Line With Comparables But Getting More Expensive; Fair Value Moves to $26.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials Beat By A Penny On The Bottom Line But Product Sales Were Mixed. At First Glance GALNS Data Looks Mixed But May Be Good Enough. Fair Value to $24.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Consensus And Comparables: We Believe Q1 Consensus Is Somewhat High But Achievable. BMRN Is Trading In-Line With Comparables But Getting More Expensive.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Positive Preliminary Data on GALNS for MPS IVA; Acquisition of LEAD Therapeutics; 2010 Guidance Issued.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Consensus And Comparables: We Believe Q4 Consensus Is Achievable And BMRN Is Trading In-Line With Comparables; Fair Value Moves to $23.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences - Biotechnology - Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.